BRGX
Bioregenx, Inc.
Going-concern doubt
— flagged May 20, 2026
Substantial doubt about the company's ability to continue as a going concern.
“These factors raise substantial doubt about the Company’s ability to continue as a going concern. As reflected in the accompanying financial statements, for the three months ended March 31, 2026, the Company incurred a net loss of $(26,415), generated cash from operations of $26,629 and had a stockholder’s deficit of $4,533,316 as of that date. At March 31, 2026, the Company had cash on hand in the amount of $45,806. In addition, notes payable of $522,500 are in default. As a result, management has concluded that there is substantial doubt about the Company’s ability to continue as a going concern.”View the 10-Q filed May 20, 2026
Company with tickers: BRGX
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
| Line Item | Value | Unit | Period End | Form | Filed |
|---|---|---|---|---|---|
| Revenue | $426,175 | USD | 2026-03-31 | 10-Q | 2026-05-20 |
| Revenue (ASC 606) | — | ||||
| Interest & Dividend Income | — | ||||
| Net Interest Income | — | ||||
| Noninterest Income | — | ||||
| Total Net Revenue | — | ||||
| Premiums Earned (Net) | — | ||||
| Cost of Revenue | $77,887 | USD | 2026-03-31 | 10-Q | 2026-05-20 |
| Gross Profit | $348,288 | USD | 2026-03-31 | 10-Q | 2026-05-20 |
| Operating Expenses | $398,052 | USD | 2026-03-31 | 10-Q | 2026-05-20 |
| Research & Development | — | ||||
| Operating Income | $-49,764 | USD | 2026-03-31 | 10-Q | 2026-05-20 |
| Net Income | $-26,415 | USD | 2026-03-31 | 10-Q | 2026-05-20 |
| EPS (Basic) | $0.00 | USD/shares | 2026-03-31 | 10-Q | 2026-05-20 |
| EPS (Diluted) | $0.00 | USD/shares | 2026-03-31 | 10-Q | 2026-05-20 |
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
By Product & Service (USD)
| Component | 2021-12-31 | 2022-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Nutritional | — | — | $1,824,723 | $1,628,306 |
| Medical Testing | — | — | $587,617 | $207,934 |
| Wellness Devices | — | — | $186,296 | $25,419 |
| Other Sales | — | — | $3,203 | $884 |
| Findit Services | $197,447 | $42,159 | — | — |
| Sales Of Essential Oils | $1,137 | — | — | — |